Resistant superbug's arrival highlights the need for more effective diagnostics
01 July 2016
Politicians and medical experts worldwide alike have decried the lack of innovation in antibiotics – an area that has been neglected for three decades – but another area is turning out to be just as important: diagnostics.
The biotech IPO feast flags as investors lose their appetite for R&D risk
30 June 2016
There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Funds chased each other for huge returns. CEOs became overnight millionaires.
Pharmacy Managers Unleash Big Data
30 June 2016
OptumRx was doing a routine analysis of a client’s prescription-drug claims when it noticed something odd. The company’s spending on acne medicine seemed high compared with those of other customers. Digging into the usage data for clues, the pharmacy arm of the health insurer, UnitedHealth Group, found that employees had been prescribed newer brand-name acne drugs that were, for the most part, combinations of older generic medicines. OptumRx began requiring patients to begin treatment with the cheaper remedies and switch to the pricier ones only if the others proved ineffective. Within six months, the 60,000-employee company had saved more than $70,000, OptumRx says.
ReVision Optics Receives FDA Approval for the Raindrop® Near Vision Inlay
29 June 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces receipt of U.S. Food and Drug Administration (FDA) approval for the Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia. The Raindrop Near Vision Inlay is indicated to improve near vision by reshaping the anterior curvature of the cornea in presbyopic patients who have emmetropic refractions (+1.00 D to -0.50 D).
Diabetes Breakthrough Nears With Medtronic’s Artificial Pancreas
29 June 2016
The discovery of insulin almost a century ago was one of the most remarkable achievements in medical history, transforming a deadly disease into a manageable one. Now diabetics are on the cusp of another breakthrough, one that could ease the endless task of manually testing and adjusting their blood sugar levels.
Reality check from Eric Lander: Majority of cancer cures will take decades
29 June 2016
Softening the current optimism about curing cancer, a leading figure in genetics and disease research says it’ll take decades to transform the majority of cancers into chronic diseases instead of lethal ones.
FDA breaks up international scam putting bogus FDA labels on drugs
29 June 2016
The FDA has put another operator out of business that was falsely selling foreign-made drugs as if they were FDA-approved, but this one put a new twist on the practice. He bought drugs manufactured in India and elsewhere, doctored them to appear as if they were made in the U.S. and FDA-approved, then sold them to unsuspecting clients in other countries instead of the U.S.
China's biopharma boom at tipping point for growth, WuXi's Li says
29 June 2016
Explosive growth for China's biopharma industry spurred by the return of talent after high-profile stints at companies and universities in the U.S. will accelerate in the coming two decades, the chief of the country's top CRO tells Bloomberg.
28 June 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome (FXS). The investigator selected Clinical Global Impression of Improvement (CGI-I), which is a broad scale to assess the overall improvement across the entire Fragile X Syndrome, as the primary endpoint of the study.
GlobalData on the difficulties and opportunities of Brexit for pharma
28 June 2016
While the exit of the UK from the EU undoubtedly creates significant issues for the UK pharmaceutical industry in ensuring highly regulated European markets remain open to business, opportunities remain for the sector to thrive, according to research and consulting firm GlobalData.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024